Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety & Immunogenicity of S. aureus Toxoids rAT and rLukS-PV in Healthy Volunteers
NCT01011335Phase 2Completed
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Nov 2009
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of antithrombin alfa, monovalent rLukS-PV in Staphylococcus aureus infection, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Started Nov 2009; status: completed.
02
Drugs
antithrombin alfamonovalent rLukS-PV
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT01011335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011335.